Navigation Links
Multiple deaths forces cancer trial to be called off

Cell Therapeutics a biotechnology firm based in Seattle has called off further enrollment for the clinical trial it had initiated early this year following the untimely deaths// of few of the patients who were participating in the clinical trial to prove the efficacy of the cancer drug Xyotax.

The CEO of the company James Bianco has reiterated that the deaths of the volunteer s who were cancer patients do not seem to have been triggered of by any kind of toxic effect of the drug Xyotax. He declined to divulge how many patients had actually succumbed to death after the clinical tests were initiated .However he did admit that more women have died from lung cancer in the group that were being given the drug than the group that were put on a standard chemotherapy drug.

The deaths have been certified to have been caused simply because of progression of the lung cancer. Most of the patients participating suffered from advanced cancer. The probability of the clinical tests progressing now is bleak until the data relating to present deaths are studied which would be anything more than six months. This could mean severe financial setbacks for the company.

This clinical trial which had been termed as Pioneer was unique in having enrolled only women who were suffering from lung cancer. It was publicized in a big way with enrollment made at 170 medical centers globally last April, and had planned to study about 600 patients to prove the efficacy of Xyotax in increasing the life span of patients with lung cancer using a regularly used chemotherapy agent coupled with a polymer which is supposed to help in making the it more user friendly.

The same drug in previous tests conducted last year failed to prove itself in improving survival rates in general but showed significant benefits among women. The company has announced that once the study resumes women normal estrogen levels who had already enrolled would be welcome to benefit from tr ials with Xyotax.

Incidentally this company had conducted a similar trial way back in 2003 when it was prematurely halted when deaths of patients were reported with a sudden fall of white blood cells in their bodies owing to drug toxicity. This time around the drug dosage and concentration was severely tapered to avoid toxicity.
MST
'"/>




Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Multiple organ disease cured by genes
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. Life Quality For Patients With Multiple Sclerosis
5. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
6. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
7. Hope For Patients With Multiple Sclerosis
8. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
9. Debating The Link Between Sex Hormones And Multiple Sclerosis
10. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
11. Decreasing Multiple Births By Single Embryo Transfers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: